Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 
168 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lonsurf (trifluridine/tipiracil) / Otsuka
2017-000292-83: Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer

Ongoing
4
195
Europe
Film-coated tablet, Lonsurf
Servier Deutschland GmbH, Servier Deutschland GmbH
Histologically or cytologically confirmed UICC stage IV carcinoma of colon or rectum with metastasis (metastatic colorectal cancer) with need for treatment due to progression, metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
ChiCTR2100052512: Small sample clinical observation of bevacizumab combined with TAS-102 (Suyuan) and irinotecan in the second-line treatment of RAS wild-type metastatic colorectal cancer

Recruiting
4
50
 
bevacizumab combined with TAS-102 (Suyuan) and irinotecan
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Anhui Provincial Cancer Hospital
Colorectal cancer
 
 
2019-000276-41: Study on the effects of metformin and cimetidine on the exposure of trifluridine/tipiracil (lonsurf®) in patients with a metastatic colorectal carcinoma Studie naar het effect van metformine en cimetidine op de blootstelling van trifluridine/tipiracil (lonsurf®) bij patiënten met gemetastaseerd colorectaal carcinoom.

Not yet recruiting
4
Europe
Metformin, Cimetidine, Tablet, Lonsurf, Metformin, Cimetidine
Erasmus MC, Servier Nederland Farma B.V.
patients with mCRC with an indication for lonsurf treatment. patiënten met gemetastaseerd colorectaalcarcinoom met een indicatie voor behandeling middels Lonsurf., patients with metastatic bowel cancer patiënten met uitgezaaide darmkanker, Diseases [C] - Cancer [C04]
 
 
ChiCTR2100047021: A randomized, controlled, multicenter clinical trial of Fruquintinib combined with TAS-102 with Fruquintinib in the treatment of advanced metastatic colorectal cancer with standard treatment failure

Recruiting
4
274
 
Give fruquintinib combined with TAS-102 ;fruquintinib
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Self-funded and Qilu Pharmaceutical Co., Ltd
colorectal cancer
 
 
ChiCTR2100052373: A single-arm clinical trial evaluating the safety and effectiveness of regorafenib combined with TAS-102 and multi-target single-center stereotactic radiotherapy (SBRT) as a third-line treatment for advanced colorectal adenocarcinoma with multiple liver and/or lung metastases

Not yet recruiting
4
174
 
Regorafenib ;TAS-102 ;single-center stereotactic radiotherapy (SBRT)
The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University, self-funded
Colorectal adenocarcinoma
 
 
ChiCTR2300071752: Regorafenib in combination with TAS-102 for patients with metastatic colorectal cancer refractory to standard therapies: a prospective, single-arm, multi-center, phase II study

Not yet recruiting
4
28
 
Regorafenib plus TAS-102
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, raise independently
colorectal cancer
 
 
ChiCTR2400088929: Efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib for third-line treatment of unresectable metastatic colorectal cancer.

Not yet recruiting
4
200
 
trifluridine/tipiracil combined with fufuquitinib; Fufuquitinib; Trifluridine/tipiracil
The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University, Medical philanthropy fund of China Social Assistance Foundation
colorectal cancer
 
 
ChiCTR2300078241: Efficacy and safety study of fruquintinib combined with TAS-102 in the third-line treatment of advanced colorectal cancer

Recruiting
4
35
 
TAS102 in combination with furquintinib
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, China Social Assistance Foundation
Colorectal cancer
 
 
ChiCTR2400091149: Traflouridine tepiridine (TAS-102) combined with oxaliplatin in the perioperative treatment of elderly patients with gastric / gastroesophageal junction adenocarcinoma: an open, single arm, single center clinical study

Not yet recruiting
4
30
 
oxaliplatin+TAS-102
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Beijing weiai Public Welfare Foundation
gastric cancer
 
 
ROBiTS, jRCTs031210544: JCOG2014: Randomized phase III study of bi-weekly trifluridine/tipiracil plus bevacizumab vs trifluridine/tipiracil alone for chemorefractory metastatic colorectal cancer

Active, not recruiting
3
420
Japan
Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Avastin (bevacizumab) - Roche
Shizuoka Cancer Center, National Cancer Center Japan
Colorectal cancer
 
 
SHR-A1811-309, CTR20234257: A randomized, open-label, active-controlled, multicenter phase III clinical study of SHR-A1811 for injection versus investigator-selected treatment regimen in patients with advanced colorectal cancer who have failed treatment with oxaliplatin, fluorouraci

Ongoing
3
120
China
trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Stivarga (regorafenib) - Bayer, Fruzaqla (fruquintinib) - Takeda
Shanghai Hengrui Pharmaceutical Co., Ltd./ Jiangsu Hengrui Pharmaceutical Co., Ltd./ Suzhou Shengdia Biopharmaceutical Co., Ltd
Colorectal cancer
 
 
2020-004289-20: A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal Cancer

Not yet recruiting
3
434
Europe
Lenvatinib, E7080, Concentrate for solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475), STIVARGA, LONSURF
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Colorectal Carcinoma, Colorectal cancer, Diseases [C] - Cancer [C04]
 
 
SOLSTICE, NCT03869892 / 2017-004059-22: Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Active, not recruiting
3
856
Europe, RoW
Trifluridine/tipiracil hydrochloride (S95005), Capecitabine, Bevacizumab experimental, Bevacizumab control
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Metastatic Colorectal Cancer
06/21
12/25
2021-001309-60: MK-4280A Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer MK-4280A en comparación con el tratamiento de referencia en pacientes con Cancer Colorrectal metastásico positivo para PD-L1 tratados previamente

Not yet recruiting
3
432
Europe, RoW
favezelimab / pembrolizumab, TRIFLURIDINE / TIPIRACIL, MK-4280A, Solution for infusion, Film-coated tablet, Stivarga 40 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Metastatic Colorectal Cancer cáncer colorrectal metastásico, Metastatic Colorectal Cancer cáncer colorrectal metastásico, Diseases [C] - Cancer [C04]
 
 
SUNLIGHT, NCT04737187 / 2020-001976-14: Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

Checkmark SUNLIGHT trial data in refractory mCRC at ASCO-GI 2023
Jan 2023 - Jan 2023: SUNLIGHT trial data in refractory mCRC at ASCO-GI 2023
Completed
3
492
Europe, US, RoW
Trifluridine/Tipiracil, TAS102, S 95005, Lonsurf, Bevacizumab, Avastin
Taiho Oncology, Inc., Institut de Recherches Internationales Servier
Refractory Metastatic Colorectal Cancer
07/22
09/23
LEAP-017, NCT04776148 / 2020-004289-20: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/)

Completed
3
480
Europe, Canada, Japan, US, RoW
pembrolizumab, KEYTRUDA®, MK-3475, lenvatinib, MK-7902, E7080, regorafenib, STIVARGA®, REGONIX®, TAS-102 (trifluridine and tipiracil), LONSURF®
Merck Sharp & Dohme LLC, Eisai Inc.
Colorectal Neoplasms
02/23
09/24
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
COLSTAR, NCT05223673 / 2021-003151-41: Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Terminated
3
7
Europe, Japan, US
Futuximab/modotuximab, Trifluridine/Tipiracil
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Metastatic Colorectal Cancer
06/23
06/23
2018-004845-18: LON-GAS A randomized study with TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without Bevacizumab in patients with pre-treated cancer in esophagus or stomach LON-GAS Et lodtrækningsforsøg med TRIFLURIDINE/TIPIRACIL (FTD/TPI) med eller uden bevacizumab til patienter med tidligere behandlet kræft i spiserør, mavemund eller mavesæk

Not yet recruiting
3
106
Europe
Solution for infusion, Film-coated tablet, Avastin, Lonsurf
Lene Bæksgaard Jensen, Danish Cancer Society, Novo Nordisk Foundation, Servier Danmark A/S
TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in patients with platinum-refractory esophago-gastric adenocarcinoma Et randomiseret fase III studie med TRIFLURIDINE/TIPIRACIL (FTD/TPI) med eller uden bevacizumab til patienter med platin-resistent Øsofago-gastrisk adenocarcinom (LON-GAS)., Randomised trial in patients with advanced cancer in esophagus and stomach with Lonsurf with or without bevacizumab Lodtrækningsforsøg til patienter med udbredt kræft i spiserør, mavemund og mavesæk med Lonsurf med eller uden bevacizumab, Diseases [C] - Cancer [C04]
 
 
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
KEYFORM-007, NCT05064059: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
favezelimab/pembrolizumab, MK-4280A, regorafenib, STIVARGA®, REGONIX®, TAS-102, LONSURF®
Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
02/25
SHR-A1811-309, NCT06199973: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Recruiting
3
120
RoW
SHR-A1811, TAS-102, Regorafenib , Fruquintinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Colorectal Cancer
04/26
06/26
CLARITY-Gastric 01, NCT06346392: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Recruiting
3
589
Europe, Canada, Japan, US, RoW
AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib
AstraZeneca
Gastric Cancer, Gastroesophageal Junction Cancer
04/26
10/26
NOTABLE-308, NCT06343116: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not yet recruiting
3
420
NA
Nimotuzumab injection, Taixinsheng, Placebo, Trifluridine/tipiracil
Biotech Pharmaceutical Co., Ltd.
Refractory Metastatic Colorectal Cancer
04/27
04/27
TroFuse-015, NCT06356311: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Recruiting
3
450
Europe, Canada, Japan, US, RoW
Sacituzumab tirumotecan, SKB264. MK-2870, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medication, Supportive care measures
Merck Sharp & Dohme LLC
Gastroesophageal Cancer
01/27
05/28
KEYFORM-007, NCT05600309: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Active, not recruiting
3
94
RoW
favezelimab/pembrolizumab, MK-4280A, regorafenib, STIVARGA®, REGONIX®, TAS-102, LONSURF®
Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
02/25
PRABITAS, jRCTs041230120: A pragmatic, randomized phase III trial of bi-weekly versus conventional schedule of TAS-102 plus bevacizumab for metastatic colorectal cancer

Recruiting
3
890
Japan
Lonsurf (trifluridine/tipiracil) - Otsuka, Avastin (bevacizumab) - Roche
Aichi Cancer Center Hospital
colorectal cancer
 
 
AndroMETa-CRC-, NCT06614192: A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer

Recruiting
3
460
Japan, US, RoW
ABBV-400, Trifluridine/Tipiracil, LONSURF, Bevacizumab
AbbVie
Metastatic Colorectal Cancer
04/29
04/29
RELATIVITY-123, NCT05328908 / 2021-004285-35: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Calendar Jan 2025 - Dec 2025: Data readout from RELATIVITY-123 trial for 2L+ MSS metastatic CRC
Active, not recruiting
3
700
Europe, Canada, Japan, US, RoW
Nivolumab-relatlimab FDC, BMS-986213, Regorafenib, Stivarga, TAS-102, Trifluridine/Tipiracil, Lonsurf
Bristol-Myers Squibb
Colorectal Neoplasms
07/25
09/25
CodeBreak 300, NCT05198934 / 2021-004008-16: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Jul 2023 - Dec 2023: Data readout from CodeBreak 300 trial for colorectal cancer
Active, not recruiting
3
160
Europe, Japan, US, RoW
Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Trifluridine and Tipiracil, Lonsurf, Regorafenib, Stivarga
Amgen
Colorectal Cancer (CRC)
03/25
03/25
NCT06850090: Neoadjuvant Radiotherapy for Rectal Adenocarcinoma with Capecitabine Versus TAS-102

Not yet recruiting
3
228
RoW
TAS-102, Capecitabine
Shandong Cancer Hospital and Institute
Rectal Cancer, Rectal Cancer Patients
04/27
04/28
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
2017-000364-15: A trial testing TAS-102 therapy versus an alternative high-dose, intermittent scheduling for sunitinib in patients with metastatic colorectal carcinoma. Een onderzoek bij patiënten met uitgezaaid dikke darm en/of endeldarm kanker die een indicatie hebben voor behandeling met TAS-102 waarbij de behandeling met TAS-102 wordt vergeleken met een behandeling met hoge dosis, intermitterend, sunitinib.

Ongoing
2/3
60
Europe
sunitinib, L01XE04, Tablet, Sutent
VU University Medical Center, Department of Medical, VU University Medical Center, Department of Medical
Advanced colorectal tumors Gemetastaseerd colorectaal carcinoom, Metastasized (spread) or inoperable colorectal cancer Uitgezaaid (verspreid) of inoperabel colorectaal carcinoom, Diseases [C] - Cancer [C04]
 
 
SUNRISE-CRC, NCT03909724: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Recruiting
2/3
60
Europe
Sunitinib Malate, Sutent, TAS 102, Lonsurf
Amsterdam UMC, location VUmc
Colorectal Cancer, Metastasis
07/21
07/22
WJOG11018G, jRCTs041190100: Phase 2 trial of FOLFIRI plus ziv-aflibercept in patients with colorectal cancer previously treated with oxaliplatin, fluoropyrimidins, bevacizumab, and trifluridine/tipiracil

Completed
2
25
Japan
Zaltrap (ziv-aflibercept IV) - Sanofi, irinotecan - Generic mfg., leucovorin calcium - Generic mfg., 5-fluorouracil - Generic mfg.
Kansai Medical University Hospital, West Japan Oncology Group
Colorectal Cancer
 
 
jRCTs041210105: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab (Ram) for advanced gastric cancer

Active, not recruiting
2
32
Japan
Lonsurf (trifluridine/tipiracil) - Otsuka, Cyramza (ramucirumab) - Eli Lilly
Nagoya University Graduate School of Medicine
Gastric cancer
 
 
jRCTs041220120: Phase II study of FTD/TPI plus RAM compared with FTD/TPI for advanced gastric cancer (WJOG15822G)

Active, not recruiting
2
110
Japan
Lonsurf (trifluridine/tipiracil) - Otsuka, Cyramza (ramucirumab) - Eli Lilly
Saitama Cancer Center, Naoki Takahashi,TAIHO PHARMACEUTICAL CO., LTD.
gastric cancer, esophagogastric junction adenocarcinoma
 
 
2016-005241-23: Lonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer. A randomized phase II study Lonsurf med eller uden bevacizumab til patienter med kemo-refraktær metastatisk kolorektal cancer Randomiseret fase II forsøg

Ongoing
2
80
Europe
Lonsurf, Coated tablet, Concentrate for solution for infusion, Lonsurf, Avastin
Odense Universitetshospital, Servier Danmark A/S
Metastatic, non-resectable and chemo-refractory colorectal cancer Metastatisk, ikke-resektabel og kemo-refraktær kolorektal-kræft, The purpose of this study is to evaluate the efficacy and tolerability of Lonsurf with or without bevacizumab in Caucasian patients with chemo-refractory metastatic colorectal adenocarcinoma. Formålet er at evaluere effekt og tolerabilitet af Lonsurf med eller uden bevacizumab til beh. af patienter med kemo-resistent kræft i tyktarm eller endetarm med spredning til andre dele af kroppen., Diseases [C] - Cancer [C04]
 
 
NCT03278106: TAS-102 in Treating Advanced Biliary Tract Cancers

Completed
2
28
US
Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102, Lonsurf, TAS-102, Trifluridine/Tipiracil
Mayo Clinic, National Cancer Institute (NCI)
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVB Gallbladder Cancer AJCC v7
11/18
09/21
2018-001600-12: Phase II study of Panitunumab plus Cetuximab in pretreated in patients with metastatic colorectal cancer Studio di fase II con Panitunumab più Cetuximab in pazienti con cancro del colon retto metastatico

Not yet recruiting
2
112
Europe
VECTIBIX, LONSURF, [VECTIBIX], [LONSURF], Concentrate for solution for infusion, Coated tablet, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE
Dipartimento di Medicina di Precisione - Università degli studi della Campania "L. Vanvitelli", Amgen
mCRC Tumore del colon-retto metastatico, Colorectal cancer Tumore del colon-retto, Diseases [C] - Cancer [C04]
 
 
2018-002936-26: Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancer

Not yet recruiting
2
28
Europe
TAS-102, Irinotecan, Film-coated tablet, Concentrate for solution for infusion, Lonsurf
Heinrich-Heine-University Düsseldorf, SERVIER Deutschland GmbH
Patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment., Patients with advanced, non resectable or metastatic bile duct cancer after failure to respond to a previous gemcitabine treatment., Diseases [C] - Cancer [C04]
 
 
2019-004196-39: A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer

Not yet recruiting
2
340
Europe
Regorafenib, trifluridine/tipiracil, L01XE21, Tablet, Stivarga, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE
UNICANCER, Bayer HealthCare Pharmaceuticals Inc.
The study population will consist of male and female patients aged ≥ 18 years old with metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapies, as well as EGFR and VEGF inhibitors in patients eligible for these treatments., metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapies, as well as EGFR and VEGF inhibitors in patients eligible for these treatments., Diseases [C] - Cancer [C04]
 
 
2019-004223-20: Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519

Not yet recruiting
2
153
Europe
Bevacizumab, Film-coated tablet, Concentrate for solution for infusion, Lonsurf, Vectibix
Charité Universitätsmedizin Berlin, Servier
Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519, metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
2020-004636-25: Incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain in the adjuvant or metastatic setting.

Not yet recruiting
2
49
Europe
Lonsurf, oxaliplatin, Tablet, Solution for infusion, Lonsurf, oxaliplatin
GERCOR, Servier
colorectal or oesogastric adenocarcinoma, colorectal or oesogastric adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
NCT04072445: Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Completed
2
28
US
Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Mayo Clinic, National Comprehensive Cancer Network
Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma, Refractory Gallbladder Carcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
08/21
08/21
ACCRU-GI-1618, NCT03981614: Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Completed
2
102
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
08/21
07/24
NCT03686488: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed
2
23
US
TAS 102, Lonsurf, Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
H. Lee Moffitt Cancer Center and Research Institute
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
01/22
05/24
2021-002169-16: USE OF CIRCULATING TUMOR DNA TEST TO INTENSIFY POST-OPERATIVE TREATMENT OF PATIENTS WITH RESECTED COLON CANCER. UTILIZZO DEL DNA TUMORALE CIRCOLANTE PER INTENSIFICARE IL TRATTAMENTO POST-OPERATORIO DEI PAZIENTI CON TUMORE DEL COLON OPERATO.

Not yet recruiting
2
459
Europe
Calcio Levofolinato, Oxaliplatino, Capecitabina, Irinotecan, LONSURF, Fluorouracile, Lonsurf, [Calcio Levofolinato], [Oxaliplatino], [Capecitabina], [Irinotecan], [TAS-102], [Fluorouracile], Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Solution for injection/infusion, Solution for infusion, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE, LONSURF - 20 MG/8,19 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE
Fondazione GONO, SERVIER ITALIA SPA, Servier Affaires Médicales, Fondazione GONO, Foundation Medicine Inc
STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS. TUMORE DEL COLON RESECATO IN STADIO III O IN STADIO II AD ALTO RISCHIO., RESECTED COLON CANCER Tumore del colon operato, Diseases [C] - Cancer [C04]
 
 
ChiCTR2200058610: Clinical study on the efficacy and safety of bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer

Not yet recruiting
2
30
 
Bevacizumab in combination with TAS-102
Xuchang Central Hospital; Xuchang Central Hospital, self-funded by researchers
colorectal cancer
 
 
NCT06403709: Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Active, not recruiting
2
35
RoW
Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab, Irinotecan+TAS-102+Bevacizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
08/24
08/26
2022-000273-81: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy

Not yet recruiting
2
118
Europe
LONSURF, ELVORINE, Coated tablet, Solution for infusion, Capsule, LONSURF, ELOXATINE, FOLINATE DE CALCIUM, 5-Fluorouracil, capecitabine, ELVORINE
UNICANCER, Laboratoire SERVIER
Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy., Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer, Diseases [C] - Cancer [C04]
 
 
ChiCTR2100051262: Thalidomide combined with Trifluridine-Tipiracil Hydrochloride Mixture versus Trifluridine-Tipiracil Hydrochloride Mixture in the third-line or higher treatment of advanced colorectal cancer: a randomized, controlled, multicenter phase II clinical study

Recruiting
2
120
 
Thalidomide ;None
Fujian Cancer Hospital; Fujian Cancer Hospital, Changzhou Pharmaceutical Factory Co., Ltd.
advanced colorectal cancer
 
 
NCT04097028: Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Active, not recruiting
2
22
US
Trifluridine and Tipiracil Hydrochloride, 733030-01-8, Lonsurf, TAS 102, Thymidine, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Oxaliplatin, 1-OHP, 266046, 61825-94-3, [(1R,-2R)-1,2-cyclohexanediamine-N,N''][oxalato (2--)-O,O'']platinum, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, oxalato (1R,2R-cyclohexanediamine)platinum(II), oxalato (trans-l-1,2-diaminocyclohexane)platinum(II), Oxalatoplatin, OXALIPLATIN,, RP 54780, RP-54780, SR-96669, trans-l DACH oxalatoplatinum
Roswell Park Cancer Institute, National Comprehensive Cancer Network
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
12/22
12/25
TACTIC, NCT05266820: Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Recruiting
2
120
RoW
Thalidomide, Thalidomide Tablets produced by Changzhou Pharmaceutical Factory Co. LTD, TAS-102
Fujian Cancer Hospital
Metastatic Colorectal Cancer
12/22
12/23
2020-001075-32: A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy Eine Pilotstudie mit Ramucirumab über den Progress hinaus in Kombination mit TAS-102 bei Patienten mit fortgeschrittenem oder metastasiertemAdenokarzinom des Magens oder des ösophagogastralen Übergangs,nach Therapieversagen einer Ramucirumab-basierten Therapie

Not yet recruiting
2
20
Europe
Ramucirumab, TAS102, Concentrate for solution for infusion, Film-coated tablet, Cyramza® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf
Institut für Klinische Krebsforschung IKF GmbH, Lilly Deutschland GmbH
advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, Diseases [C] - Cancer [C04]
 
 
NCT04894123 / 2020-004636-25: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients

Terminated
2
1
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin
GERCOR - Multidisciplinary Oncology Cooperative Group, Servier
Colorectal Adenocarcinoma, Oesogastric
02/23
02/23
NCT05314101: TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Recruiting
2
25
RoW
Tislelizumab, bevacizumab, TAS-102
Fujian Cancer Hospital
Immunotherapy, Colorectal Cancer
02/23
02/24
BEV-TASIRI, NCT06242067: Second-line Treatment of Metastatic Colorectal Cancer

Recruiting
2
50
RoW
Trifluridine/tipiracil, Irinotecan, Bevacizumab
Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Shandong Provincial Hospital, Qianfoshan Hospital, Binzhou People's Hospital, Binzhou Medical University, Yantai Yuhuangding Hospital, Linyi Tumour Hospital
Metastatic Colorectal Cancer
12/24
12/26
NCT04923529: TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Active, not recruiting
2
28
RoW
TAS 102
The University of Hong Kong, Taiho Pharmaceutical Co., Ltd.
Pancreas Cancer
03/24
12/24
NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Recruiting
2
22
US
TAS 102
Rahul Parikh, Taiho Oncology, Inc.
Bladder Cancer
07/23
01/24
TABAsCO, NCT04109924: TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the Study

Active, not recruiting
2
42
US
Irinotecan, (+)-(4S)-4, 11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione, (+)-7-ethyl-10-hydroxycamptothecine 10-[1,4''-bipiperidine]-1''-carboxylate,, 616348,, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, 728073, 97682-44-5, Bevacizumab, 216974-75-3, 704865, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain,, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Trifluridine and Tipiracil Hydrochloride, 733030-01-8, Lonsurf, TAS 102, TAS-102, Thymidine, Alpha, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil,
Roswell Park Cancer Institute, National Comprehensive Cancer Network
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
07/24
07/25
TAS-102 NEC, NCT04042714: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

Recruiting
2
14
US
All patients- TAS-102, Trifluridine, Tipiracil
Baylor Research Institute, Taiho Oncology, Inc.
High-grade Extra Pulmonary Neuroendocrine Cancer
08/23
08/23
NCT04808791: iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed
2
7
Canada
Irinotecan, Camptosar, Oxaliplatin, Eloxatin, TAS 102 (Trifluridine/Tipiracil), Lonsurf
AHS Cancer Control Alberta
Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma
07/23
07/23
TIBET, NCT04489173: TAS102 in Patients with ER-positive, HER2-negative Advanced Breast Cancer

Active, not recruiting
2
52
Europe
trifluridine/tipiracil, Lonsurf, TAS102
Borstkanker Onderzoek Groep, Erasmus Medical Center, UMC Utrecht, Servier, BOOG Study Center
Breast Neoplasm, Chemotherapy Effect
01/24
12/24
NCT05004831: Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Recruiting
2
54
RoW
fruquintinib plus TAS-102
Sun Yat-sen University
Metastatic Colorectal Cancer
09/23
09/24
TRITICC, NCT04059562: Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

Completed
2
28
Europe
Combination of Lonsurf® and Irinotecan
Heinrich-Heine University, Duesseldorf, Servier
Cholangiocarcinoma
01/24
01/24
LONGBOARD, NCT04166604: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Active, not recruiting
2
176
Europe
Trifluridine/Tipiracil, Lonsurf
GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
11/23
11/24
PULSE, NCT03992456: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Active, not recruiting
2
12
US
Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Regorafenib, BAY 73-4506, Regorafenib Anhydrous, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
12/23
10/24
NCT05029102: TAS-102 and Anlotinib in ≥3 Lines mGC

Recruiting
2
45
RoW
TAS 102, Anlotinib
Zhejiang University
Gastric Cancer
12/24
12/24
NCT04683965: Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

Active, not recruiting
2
27
RoW
Pemetrexed, TAS-102, LONSURF, Bevacizumab, Avastin
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Colorectal Neoplasms
01/24
05/24
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT06293014: TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Recruiting
2
224
RoW
TAS-102+bevacizumab, Trifluridine and Tipiracil Hydrochloride Tablets; bevacizumab, Standard chemotherapy+bevacizumab, Bevacizumab
Henan Cancer Hospital
Colorectal Cancer
10/25
11/26
NCT04294264: TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Active, not recruiting
2
50
US
Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
03/24
03/26
NCT06485713: Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

Recruiting
2
200
RoW
trifluridine/tipiracil combined with fufuquitinib, fufuquitinib, Trifluridine/tipiracil
First Affiliated Hospital of Wenzhou Medical University
Metastatic Colorectal Cancer, Drug Therapy
06/26
06/26
NCT05343013: TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Suspended
2
25
US
TAS-102, trifluridine, tipiracil, Lonsurf
M.D. Anderson Cancer Center, Taiho
Colorectal Cancer
05/25
05/25
E-BiTS, jRCTs041220085: Phase2 study of intrapatient dose-escalation of biweekly trifluridine/tipiracil + bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies ( study)

Active, not recruiting
2
36
Japan
Lonsurf (trifluridine/tipiracil) - Otsuka, Avastin (bevacizumab) - Roche
Aichi Cancer Center Hospital
metastatic colorectal cancer
 
 
ACCRU-GI-2003, NCT05356897: Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Withdrawn
2
30
US
Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102, Tucatinib, ARRY-380, Irbinitinib, ONT-380, Tukysa
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
09/24
09/24
STARLIGHT, NCT06563986: FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Systemic treatment (FTD-TPI and bevacizumab), Radioembolization with 166-Ho microspheres
UMC Utrecht
Metastatic Colorectal Cancer
01/28
06/28
NCT04660760: Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting
2
116
US
Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
07/24
05/26
NCT05481463: Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Recruiting
2
20
RoW
Surufatinib, TAS-102
Sun Yat-sen University
Pancreatic Neoplasms
08/24
08/25
TACT-D, NCT03844620: Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting
2
100
US
Best Practice, standard of care, standard therapy, Laboratory Procedure, Lab Test, Lab Tests, Laboratory Test, Test, Tests, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Regorafenib, BAY 73-4506, Stivarga, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/26
08/26
TOBACO, NCT05077839: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

Recruiting
2
184
RoW
Trifluridine/Tipiracil, TAS-102
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Colorectal Cancer
08/24
08/25
ChiCTR2300070070: BC001 combined TAS-102 in a multicenter phase II clinical study in patients with metastatic colorectal cancer who have failed or not tolerated first-and second-line standard therapy

Not yet recruiting
2
56
 
BC001 combined with TAS-102 treatment
Beijing University Cancer Hospital; Beijing University Cancer Hospital, Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd.
Patients with metastatic colorectal cancer who fail or do not tolerate first-line and second-line standard therapy
 
 
NCT04280536: Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

Recruiting
2
86
RoW
Cohort A, trifluridine/tipiracil, TAS-102 [Lonsurf], Cohort B
National University Hospital, Singapore
Breast Cancer
10/24
10/24
NCT04627961: A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
33
RoW
TAS-102, LONSURF
National University Hospital, Singapore
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
10/24
10/24
SHORT, NCT04417699: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Completed
2
13
US
TAS 102, Tipiracil hydrochloride, Oxaliplatin, Eloxatin
Providence Health & Services, Taiho Oncology
Rectal Cancer
12/23
02/24
NCT06711471: Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Recruiting
2
31
RoW
trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
LIN YANG
Gastric Cancer Adenocarcinoma Metastatic
11/26
11/27
SOREGATT, NCT04450836 / 2019-004196-39: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Active, not recruiting
2
340
Europe
Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib
UNICANCER, Bayer HealthCare Pharmaceuticals Inc.
Metastatic Colorectal Cancer
11/24
05/28
B2024-585-01, NCT06764680: Oral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

Not yet recruiting
2
57
RoW
Trifluorouracil tepidopyrimidine, Bevacizumab, Sindilizumab, IMRT
Sun Yat-sen University
Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy, Radiotherapy, Intensity-Modulated
06/26
12/26
CombiCoR-Vax, NCT06522919: Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Recruiting
2
36
Europe
Autologous Dendritic Cell (DC) Vaccine
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
04/26
09/26
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
NCT06039202: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
100
NA
CA102N, Nim-HA cinjugate, TAS-102, Trifluridine/tipiracil, Bevacizumab
Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
02/25
10/25
NCT06699836: A Phase 2 Study of Leronlimab in Combination with TAS-102 + Bevacizumab in Previously Treated Participants with MCRC

Not yet recruiting
2
60
NA
350 mg leronlimab, PRO 140, 700 mg leronlimab
CytoDyn, Inc., Syneos Health
Metastatic Colorectal Cancer (mCRC)
06/28
08/28
TASBEL, NCT06856187: Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined with Local Treatment in Advanced Colorectal Cancer

Recruiting
2
119
RoW
TAS-102+bevacizumab+local treatment, Standard chemotherapy
Fudan University
Metastatic Colorectal Cancer (CRC)
06/26
04/27
NCT06060704: Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Recruiting
2
33
RoW
Envafolimab, Trifluridine/Tipiracil, TAS-102, FTD/TPI, Bevacizumab
The First Affiliated Hospital with Nanjing Medical University
Metastatic Colorectal Cancer
03/25
09/25
NCT06680622: Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

Recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
SCRIPBOT, NCT06872606: Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Not yet recruiting
2
33
RoW
Pucotenlimab, Bevacizumab, Oxaliplatin, Trifluridine/Tipiracil Hydrochloride, Short-course radiotherapy, intracavitary brachytherapy
Sir Run Run Shaw Hospital
Rectal Adenocarcinoma
04/26
04/28
NCT06856837: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Not yet recruiting
2
140
Europe
Fruquintinib, Fruzaqla, Tislelizumab, Tevimbra, Trifluridine/tipiracil, Lonsurf, Bevacizumab, Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Colorectal Cancer
12/29
12/29
NCT06607458: Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Colorectal Cancer W/liver Dominant Disease

Not yet recruiting
2
90
NA
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil, Melphalan/HDS, Trifluridine-tipiracil plus Bevacizumab Alone, Bevacizumab
Delcath Systems Inc.
Refractory Metastatic Colorectal Cancer
12/26
10/27
NCT05364489: Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Not yet recruiting
2
20
NA
Bevacizumab combined with Oxaliplatin and TAS-102
The First Affiliated Hospital of Zhengzhou University
Advanced Colorectal Cancer
06/25
06/27
 

Download Options